Vericel (NASDAQ:VCEL) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday.

VCEL has been the topic of a number of other reports. Zacks Investment Research raised shares of Vericel from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Tuesday, March 5th. Needham & Company LLC downgraded shares of Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective on the stock. in a report on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Vericel in a report on Tuesday, January 29th. They set an “outperform” rating and a $23.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.58.

Shares of NASDAQ:VCEL opened at $19.20 on Friday. The stock has a market capitalization of $840.06 million, a P/E ratio of -137.14 and a beta of 3.04. Vericel has a fifty-two week low of $8.95 and a fifty-two week high of $21.00.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.07. The company had revenue of $31.34 million for the quarter, compared to the consensus estimate of $28.69 million. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. The firm’s quarterly revenue was up 34.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.01 EPS. As a group, analysts predict that Vericel will post 0.07 earnings per share for the current fiscal year.

In other Vericel news, CFO Gerard J. Michel sold 10,000 shares of the company’s stock in a transaction dated Monday, February 11th. The shares were sold at an average price of $17.09, for a total transaction of $170,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Paul K. Wotton sold 22,500 shares of the company’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $16.83, for a total transaction of $378,675.00. Following the sale, the director now directly owns 5,000 shares in the company, valued at $84,150. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 58,711 shares of company stock worth $1,034,580. Insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Vericel by 10.8% during the third quarter. BlackRock Inc. now owns 2,865,843 shares of the biotechnology company’s stock valued at $40,551,000 after purchasing an additional 279,408 shares during the last quarter. Meeder Asset Management Inc. increased its position in shares of Vericel by 28.7% during the fourth quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 1,284 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Vericel during the third quarter valued at about $4,725,000. Jane Street Group LLC bought a new stake in shares of Vericel during the third quarter valued at about $239,000. Finally, Teachers Advisors LLC increased its position in shares of Vericel by 531.8% during the third quarter. Teachers Advisors LLC now owns 446,296 shares of the biotechnology company’s stock valued at $6,315,000 after buying an additional 375,654 shares during the period. 84.18% of the stock is currently owned by institutional investors and hedge funds.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Featured Story: Cost of Equity For A Business, Investors

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.